

FRONTIERS IN ONCOLOGY

Nagireddy Putluri, PhD

Associate Professor, Molecular and Cellular
Biology

Academic Director, Metabolomics Core

Director, Metabolomics Shared Resource

Dan L. Duncan Comprehensive Cancer Center

Baylor College of Medicine



“STAT3 activation is a therapeutic vulnerability in metastatic bladder cancers harboring SMARCB1 loss”

***Tuesday, September 19, 2023, at 9:00 am
HSF III – Conference Room 6020
670 West Baltimore Street***

Targeted Audience

Researchers, Nurse Practitioners, Nurses, Fellows, Residents, Medical Oncologist, Hematologist, Pathologist, Students and interested personnel

Course Objectives

Participants should be informed of cutting-edge cancer treatment, diagnostic method, and preventive measures when under investigation by national and international investigator and groups. **Recognize** current areas of research in UMGCCC that are impacted by their current development. **Consider** collaboration with appropriate internal UMGCCC researchers working in cutting-edge areas.

CME Sponsorship

Sponsored by University of Maryland School of Medicine

Accreditation

The University of Maryland School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The University of Maryland School of Medicine designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ADA Statement

If you require special accommodations to attend or participate in the CME activity, please provide information about your requirements to Morgan Rogers @ 410-706-3144 at least 5 business days in advance.